Art. -Nr.: HY-106278

GW 590735

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.44%
CAS. Nr.: 343321-96-0
Formel: C₂₃H₂₁F₃N₂O₄S
Molecular Weight:478.48

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

GW 590735 Chemical Structure

CAS. Nr.: 343321-96-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle PPAR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CV-1	EC₅₀	>10 μM Compound: 25a, GW-590735	Agonist potency at PPARgamma in CV1 cells by cell based transient transfection assay Agonist potency at PPARgamma in CV1 cells by cell based transient transfection assay	[PMID: 17243659]
CV-1	EC₅₀	>10 μM Compound: GW-590735	Transactivation of Gal4-fused human PPARgamma DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of Gal4-fused human PPARgamma DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 21112784]
CV-1	EC₅₀	>10 μM Compound: GW-590735	Agonist activity at human PPARgamma-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay Agonist activity at human PPARgamma-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay	[PMID: 21515063]
CV-1	EC₅₀	0.004 μM Compound: 25a, GW-590735	Agonist potency at PPARalpha in CV1 cells by cell based transient transfection assay Agonist potency at PPARalpha in CV1 cells by cell based transient transfection assay	[PMID: 17243659]
CV-1	EC₅₀	0.01 μM Compound: GW-590735	Transactivation of Gal4-fused human PPARalpha DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of Gal4-fused human PPARalpha DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 21112784]
CV-1	EC₅₀	0.01 μM Compound: GW-590735	Agonist activity at human PPARalpha-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay Agonist activity at human PPARalpha-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay	[PMID: 21515063]
CV-1	EC₅₀	2.6 μM Compound: GW-590735	Transactivation of Gal4-fused human PPARdelta DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of Gal4-fused human PPARdelta DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 21112784]
CV-1	EC₅₀	2.6 μM Compound: GW-590735	Agonist activity at human PPARdelta-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay Agonist activity at human PPARdelta-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay	[PMID: 21515063]
CV-1	EC₅₀	2.83 μM Compound: 25a, GW-590735	Agonist potency at PPARdelta in CV1 cells by cell based transient transfection assay Agonist potency at PPARdelta in CV1 cells by cell based transient transfection assay	[PMID: 17243659]

In Vivo

GW 590735 (0.5-5 mg/kg; orally twice a day for 5 days) is able to lower LDLc and triglycerides (TG) and increase HDL cholesterol in the Apo-A-I-transgenic mouse model (male C57BL/6 mice transgenic for human ApoA-I)^[1].
GW 590735 (intravenous administration; 2.7 mg/kg; rat) treatment shows Cl, Vd, T_1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively^[1].
GW 590735 (intravenous administration; 2 mg/kg; dog) treatment shows Cl, Vd, T_1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 343321-96-0
Appearance Solid
Molecular Weight 478.48
Formel C₂₃H₂₁F₃N₂O₄S
Color White to off-white
SMILES

OC(C(C)(C)OC(C=C1)=CC=C1CNC(C2=C(C)N=C(C3=CC=C(C(F)(F)F)C=C3)S2)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Exp Mol Med

Cannabidiol triggers fatty acids β-oxidation mediated by Stat2 to facilitate intestinal stem cells regeneration post radiation. [Abstract]

2026 May;58(5):1642-1656. PMID: 42120478
bioRxiv

2025 Oct 22.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (522.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0900 mL

10.4498 mL

20.8995 mL

5 mM

0.4180 mL

2.0900 mL

4.1799 mL

10 mM

0.2090 mL

1.0450 mL

2.0900 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sierra ML, et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007;50(4):685-695. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0900 mL	10.4498 mL	20.8995 mL	52.2488 mL
	5 mM	0.4180 mL	2.0900 mL	4.1799 mL	10.4498 mL
	10 mM	0.2090 mL	1.0450 mL	2.0900 mL	5.2249 mL
	15 mM	0.1393 mL	0.6967 mL	1.3933 mL	3.4833 mL
	20 mM	0.1045 mL	0.5225 mL	1.0450 mL	2.6124 mL
	25 mM	0.0836 mL	0.4180 mL	0.8360 mL	2.0900 mL
	30 mM	0.0697 mL	0.3483 mL	0.6967 mL	1.7416 mL
	40 mM	0.0522 mL	0.2612 mL	0.5225 mL	1.3062 mL
	50 mM	0.0418 mL	0.2090 mL	0.4180 mL	1.0450 mL
	60 mM	0.0348 mL	0.1742 mL	0.3483 mL	0.8708 mL
	80 mM	0.0261 mL	0.1306 mL	0.2612 mL	0.6531 mL
	100 mM	0.0209 mL	0.1045 mL	0.2090 mL	0.5225 mL

Keywords

GW 590735

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GW 590735

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Transcription Factor-Targeted Library

Nuclear Receptor Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GW 590735

Alle PPAR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GW 590735

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Transcription Factor-Targeted Library

Nuclear Receptor Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GW 590735

Alle PPAR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GW 590735 Related Classifications

HY-106278 Related Classifications